Navigation Links
The pill for ovarian cysts
Date:3/30/2010

Ovarian endometriomas, better known as ovarian 'chocolate' cysts for the brown liquid they contain, can be easily removed by surgery. However, recurrence is common, which can cause ongoing pain and complications. A study evaluated for Faculty of 1000 suggests a simple and effective remedy the oral contraceptive pill (OCP).

In their F1000 evaluation, Neil Johnson and Shelley Reilly from Auckland, New Zealand, highlight a trial published in Fertility and Sterility that provides evidence that the OCP can reduce the reoccurrence of endometriomas after removal by surgery. They say, "this study is perhaps the only randomized controlled trial that has evaluated the effectiveness of the use of long-term postoperative OCP treatment to prevent endometrioma recurrence."

The trial consisted of 239 patients who had just undergone surgery to remove endometriomas and who were randomized into groups: those with no prescribed treatment, those taking cyclic OCPs, and those taking continuous OCPs. Patients were followed up for two years.

Women who took OCPs had significantly fewer recurring cysts. Previous studies of the effectiveness of OCPs after laparoscopic cystectomy have produced conflicting results. But long-term treatment seems to be the key: Johnson and Reilly say, "the length of treatment appears to play an important role in the efficacy of therapy".

Johnson and Reilly suggest an immediate change to current clinical practice: "If the use of an OCP is considered to reduce the risk of recurrence of an endometrioma after laparoscopic cystectomy, treatment should be given for at least two years".


'/>"/>

Contact: Constantine Stamatopoulos
press@f1000.com
Faculty of 1000: Biology and Medicine
Source:Eurekalert

Page: 1

Related biology news :

1. Dietary factors influence ovarian cancer survival rates
2. Disarming specialized stem cells might combat deadly ovarian cancer
3. Assessing lead time of selected ovarian cancer biomarkers
4. FDA approved leukemia drugs shows promise in ovarian cancer cells
5. Nanoparticle-delivered suicide genes slowed ovarian tumor growth
6. 2 reproductive factors are important predictors of death from ovarian cancer
7. Genetic factors implicated in survival gap for breast, ovarian or prostate cancer
8. Ovarian transplantation: First baby is born after a new technique
9. Ovarian transplantation: New technique gives greatly improved results in this delicate operation
10. Genetic testing for breast or ovarian cancer risk may be greatly underutilized
11. Promising new treatment option for women with recurrent ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
Breaking Biology Technology: